Lilly has been approved for the obesity-control diabetes drub ‘Trulicity’ in the domestic market

It is observed that Lilly Korea will launch the new diabetes treatment with the GLP-1 analogue type.

The drug type is the obesity-control diabetes drug, which has been highly interested by the current market.

The type, having dulaglutide as the main substance, is a diabetes product of the GLP-1 analogue.

‘Trulicity’ is the incretin-based drug, equivalent to the oral DPP-4 inhibitor which are...